parnaparin

Small moleculeexperimental

Parnaparin is an antithrombotic and belongs to the group of low molecular weight heparins. In the prevention and therapy of thromboembolic pathologies, the advent of this class of drugs represented a medical development, since they retain the same effectiveness of unfractionated heparin but with simpler dosing regimens and decreased side effects. In addition to being effective in treating proven deep vein thrombosis and thrombosis-associated phlebopathies, Parnaparin has demonstrated its thromboprophylactic efficacy in both high- and moderate-risk surgical patients. — Wikipedia

Clinical trial activity

2 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
0

Earliest trial started Jul 1, 2002 (NCT00732927)

Timeline

2000s

  1. Jan 1, 2002

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • op-21-23
  • parnaparin
  • parnaparin
  • parnaparin
  • parnaparin
  • parnaparin
  • parnaparin sodium
  • parnaparin sodium
  • parnaparin sodium
  • parnaparin sodium

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02991950Phase 3Jul 1, 2011Istituto Clinico Humanitas - Rozzano (MI), Italy
NCT00732927Phase 3Jul 1, 2002Alfa Wassermann, Ospedale di Gallarate, Ospedale di Piacenza, University of Insubria
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Alfa WassermannFor profit1012002
Istituto Clinico Humanitas - Rozzano (MI), ItalyAcademic/Hospital1112011
Ospedale di GallarateAcademic/Hospital1012002
Ospedale di PiacenzaAcademic/Hospital1012002
University of InsubriaAcademic/Hospital1112002
5 organizations
Page 1 / 1